IP Library Patent Application 17319760
Patent Application
App. No. 17/319,760

VIABLE BIOENGINEERED SKIN CONSTRUCTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/319,760
Abstract

The present disclosure is directed to viable bioengineered skin constructs.

Claims (29)

1 . A viable, bioengineered skin construct comprising

a fully stratified epithelial layer having a top surface and a bottom surface, wherein the fully stratified epithelial layer comprises human keratinocytes;

a dermal equivalent layer having a top surface and a bottom surface, wherein the dermal equivalent layer comprises human dermal fibroblasts within a matrix, the matrix comprising human collagen and optionally murine type I collagen;

wherein the bottom surface of the epithelial layer is adhered to the top surface of the dermal equivalent layer over at least 98% of one of the layers; and

wherein a dog bone-shaped sample of the skin construct fails at a load of about 0.5 N to about 1.0 N (“the failure load”) and a displacement of about 30 mm to about 45 mm when pulled to failure in uniaxial tension at a constant strain rate of 100% per minute with continuous hydration using Dulbecco's phosphate-buffered saline, and wherein the fully stratified epithelial layer fails at the same point in the load-displacement curve as the skin construct and the dermal equivalent layer fails at a displacement of about 12-18 mm or about 14-16 mm;

wherein the dog bone-shaped sample has a gauge width of 4 mm and a gauge length of 25 mm, as measured by a thickness gauge.

2 . The skin construct of claim 1 , wherein the load drops less than 10% of the failure load when the dermal equivalent layer fails.

3 . The skin construct of claim 2 , wherein the load drops less than 5% of the failure load when the dermal equivalent layer fails.

4 . The skin construct of claim 2 , wherein the load drops less than 1% of the failure load when the dermal equivalent layer fails.

5 . The skin construct of claim 1 , wherein the dermal equivalent layer fails at a displacement of about 14-16 mm and a load of about 0.1 N to about 0.5 N.

6 . The skin construct of claim 1 , wherein the skin construct has a thickness of about 100 μm to about 250 μm, or about 120 μm to about 200 μm, as measured by histology.

7 . The skin construct of claim 6 , wherein the fully stratified epithelial layer has a thickness of about 75 μm to about 120 μm and/or the dermal equivalent layer has a thickness of about 20 μm to about 80 μm, as measured by histology.

8 . The skin construct of claim 1 , wherein the keratinocytes of the epithelial layer are from a single human donor and/or the dermal fibroblasts of the dermal equivalent layer are from a single human donor, optionally different from the human donor of the keratinocytes.

9 . The skin construct of claim 8 , wherein the keratinocytes are NIKS cells or the dermal fibroblasts are normal human dermal fibroblasts.

10 . The skin construct of claim 8 , wherein the keratinocytes are NIKS cells and the dermal fibroblasts are normal human dermal fibroblasts.

11 . The skin construct of claim 1 , wherein the skin construct has a surface area of about 40 cm 2 to about 100 cm 2 .

12 . The skin construct of claim 11 , wherein the skin construct comprises human type I collagen.

13 . The skin construct of claim 12 , wherein the skin construct has at least 5 mg of human type I collagen.

14 . The skin construct of claim 12 , wherein the skin construct has at least 5.5 mg of human type I collagen or at least at least 5.8 mg of human type I collagen.

15 . The skin construct of claim 1 , wherein about 98% or more of the human type I collagen is produced by cells of the skin construct.

16 . The skin construct of claim 15 , wherein about 100% of the human type I collagen is produced by cells of the skin construct.

17 . The skin construct of claim 12 , wherein the skin construct comprises human type I collagen and murine type I collagen, wherein the murine type I collagen is not more than 90% by weight of total collagen in the skin construct.

18 . The skin construct of claim 12 , wherein the skin construct comprises human type I collagen and murine type I collagen, wherein the murine type 1 collagen is about 60% to about 90% by weight of the total type collagen in the skin construct.

19 . The skin construct of claim 1 , wherein the skin construct has a total collagen content of about 0.25 mg to about 0.45 mg per cm 2 of surface area, or about 0.29 mg to about 0.39 mg per cm 2 of surface area.

20 . A viable, bioengineered skin construct comprising

a fully stratified epithelial layer having a top surface and a bottom surface, wherein the fully stratified epithelial layer comprises human keratinocytes;

a dermal equivalent layer having a top surface and a bottom surface, wherein the bottom surface of the epithelial layer is adhered to the top surface of the dermal equivalent layer over at least 98% of one of the layers,

wherein the dermal equivalent layer comprises human dermal fibroblasts within a matrix, the matrix comprising human type I collagen, human type III collagen, human type IV collagen, and human type VI collagen and optionally murine type I collagen; and

a total collagen content of about 0.25 mg per cm 2 of surface area to about 0.45 mg per cm 2 of surface area and at least 0.05 mg per cm 2 of surface area of human type I collagen.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2021
From: ALLEN-HOFFMANN, B. LYNN; COMER, ALLEN; GRATZ, KENNETH R.; STEIGLITZ, BARRY M.
To: STRATATECH CORPORATION
Reel/Frame 056291/0382 →